Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Amnea, Celltrion, Dewpoint, Intellia.
Biopharma happenings, including deals and partnerships, and other news in brief: 89bio, Anavex, Everest Medicines, Insmed, Novabridge, Roche, Sensei, Visara.
Clinical updates, including data readouts and publications: Argenx, Avobis, Dianthus, Innocare, Johnson & Johnson, Neutrolis, Novartis, Tectonic, Unicycive, Vor, Wave.
Boehringer Ingelheim GmbH has licensed an unnamed small-molecule preclinical candidate from Kyowa Kirin Co. Ltd. in the autoimmune disease space in a deal worth up to €640 million (US$739 million).
Vera Therapeutics Inc.’s atacicept gained still more airtime at the Cantor Fitgerald health care conference held Sept. 4, and some on Wall Street believe the appetite for the BAFF and APRIL dual inhibitor could bode well for others in the same mechanistic space.
Neurodegeneration specialist Vesper Bio ApS has announced positive results from the phase Ib/II trial of its oral sortilin inhibitor VES-001 in frontotemporal dementia. The small study involved six participants who had not progressed to symptomatic disease but were carriers of mutations in the GRN gene that codes for progranulin, a growth factor that is essential for neuronal health.
The activin E mechanism of action in obesity is having something of an early stage heyday with such players as Wave Life Sciences Ltd. and Ibio Inc. talking up data that have perked the ears of Wall Street.
RSS
